The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration

J. H. Kim, T. H. Kim, H. J. Park, Y. J. Choi, J. H. Kang, K. H. Song, T. S. Koo, Kyoung Won Seo

Research output: Contribution to journalArticlepeer-review


Tulobuterol is a β2-adrenergic agonist that was the first bronchodilator approved as a transdermal patch for humans. Previous studies have examined the pharmacokinetics of tulobuterol in humans but not in the veterinary species. In this study, the pharmacokinetics of tulobuterol was examined in healthy Beagle dogs after transdermal and intravenous administration. The Cmax was 2.09 ng/mL at 16.0 h for a 0.2 mg/kg patch and 4.85 ng/mL at 13.6 h for a 0.4 mg/kg patch. The effective blood level in humans is 1-3 ng/mL, a concentration achieved using the 0.2 mg/kg patch in dogs. In conclusion, application of a 0.2 mg/kg tulobuterol patch to healthy dogs led to an apparently effective blood concentration for 24 h.

Original languageEnglish (US)
Pages (from-to)90-92
Number of pages3
JournalVeterinary Journal
StatePublished - Feb 1 2016
Externally publishedYes


  • Canine
  • Pharmacokinetics
  • Transdermal patch
  • Tulobuterol
  • β-adrenoceptor agonist

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)


Dive into the research topics of 'The pharmacokinetics of the β<sub>2</sub>-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration'. Together they form a unique fingerprint.

Cite this